D-3263 hydrochloride is an orally available TRPM8 agonist that binds to and activates TRPM8, leading to increased calcium and sodium influx, disruption of calcium and sodium homeostasis, and induction of cell death in TRPM8-expressing tumor cells; it may also reduce dihydrotestosterone (DHT) levels, contributing to its inhibitory effects on prostate cancer and benign prostatic hyperplasia (BPH).